| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
XENE Stock Overview
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada.
Xenon Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$37.89 |
| 52 Week High | US$41.39 |
| 52 Week Low | US$14.65 |
| Beta | 1.54 |
| 1 Month Change | 14.54% |
| 3 Month Change | 27.23% |
| 1 Year Change | 105.37% |
| 3 Year Change | 332.53% |
| 5 Year Change | 1,184.41% |
| Change since IPO | 260.86% |
Recent News & Updates
Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price
How far off is Xenon Pharmaceuticals Inc. ( NASDAQ:XENE ) from its intrinsic value? Using the most recent financial...
Shareholder Returns
| XENE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.5% | 1.2% | 3.2% |
| 1Y | 105.4% | -21.7% | -10.1% |
Return vs Industry: XENE exceeded the US Biotechs industry which returned -23% over the past year.
Return vs Market: XENE exceeded the US Market which returned -11.7% over the past year.
Price Volatility
| XENE volatility | |
|---|---|
| XENE Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 12.5% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: XENE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: XENE's weekly volatility has decreased from 17% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 151 | Ian Mortimer | https://www.xenon-pharma.com |
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company’s product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials.
Xenon Pharmaceuticals Inc. Fundamentals Summary
| XENE fundamental statistics | |
|---|---|
| Market Cap | US$2.36b |
| Earnings (TTM) | -US$91.84m |
| Revenue (TTM) | US$21.16m |
111.5x
P/S Ratio-25.7x
P/E RatioIs XENE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XENE income statement (TTM) | |
|---|---|
| Revenue | US$21.16m |
| Cost of Revenue | US$82.28m |
| Gross Profit | -US$61.12m |
| Other Expenses | US$30.72m |
| Earnings | -US$91.84m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.47 |
| Gross Margin | -288.81% |
| Net Profit Margin | -433.95% |
| Debt/Equity Ratio | 0% |
How did XENE perform over the long term?
See historical performance and comparison